This matters because visceral adiposity drives metabolic disease far more potently than subcutaneous fat
Anand I, Chandrashekhan Y, De Giuli F, et al
We note that in the event DefenCath TM does receive FDA marketing authorization before July 1, 2023, evaluation of this FY 2024 application would no longer be necessary, and we would propose to instead continue the new technology add-on payment for DefenCath TM for FY 2024
Those studies may help explain the parent molecules biology, but they cannot establish that the isolated seven-residue fragment reproduces every property of the full molecule
Implications for Future Obesity Therapies The new data highlight a broader shift in obesity treatment toward multi-target pharmacology
Lao XQ, Liu X, Deng HB, et al